Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01868893 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01868893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01868893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
January 31, 2014
Enrollment
20 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia